Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Regadenoson

FDA-approved product (solution, intravenous), marketed as Lexiscan, Regadenoson.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Regadenoson
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Myocardial Perfusion Imaging

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other cardiac preparations
FDA pharmacologic class
Adenosine Receptor Agonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli48.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Regadenoson in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Regadenoson with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System

    NCT03331380 · start 2018-01-05

    Registered record
    Registry ID
    NCT03331380
    Conditions
    CAD
    Interventions
    MRI scan - obj 1; MRI scans - obj 2; MRI scans - obj 3; MRI scans - obj 4
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2018-01-05
    Completion
    2028-05-31
    Enrolment
    2,950

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCAD
    InterventionMRI scan - obj 1; MRI scans - obj 2; MRI scans - obj 3; MRI scans - obj 4
    PhaseNot applicable
    Registry statusRecruiting

  • Determining the Mechanism of Myocardial Injury and Role of Coronary Disease in Type 2 Myocardial Infarction

    NCT03338504 · start 2017-10-23

    Registered record
    Registry ID
    NCT03338504
    Conditions
    Myocardial Infarction, Acute; Myocardial Ischemia; Myocardial Injury
    Interventions
    Invasive coronary angiography; CT coronary angiography; Cardiac MRI
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-10-23
    Completion
    2021-11-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction, Acute; Myocardial Ischemia; Myocardial Injury
    InterventionInvasive coronary angiography; CT coronary angiography; Cardiac MRI
    PhaseNot recorded
    Registry statusCompleted

  • A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

    NCT03236311 · start 2017-10-12

    Registered record
    Registry ID
    NCT03236311
    Conditions
    Microvascular Coronary Artery Disease
    Interventions
    SAR407899; Placebo; Adenosine; Regadenoson; 13N-ammonia; 82Rubidium
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-10-12
    Completion
    2018-07-23
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMicrovascular Coronary Artery Disease
    InterventionSAR407899; Placebo; Adenosine; Regadenoson +2 more
    PhasePhase 2
    Registry statusTerminated

  • Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT

    NCT03170817 · start 2017-03-29

    Registered record
    Registry ID
    NCT03170817
    Conditions
    Coronary Artery Disease
    Interventions
    Cardiac Perfusion Rest/Stress Digital PET/CT; N-13 ammonia; Regadenoson
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-03-29
    Completion
    2021-09-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionCardiac Perfusion Rest/Stress Digital PET/CT; N-13 ammonia; Regadenoson
    PhaseNot recorded
    Registry statusCompleted

  • Utility of Regadenoson Low-dose Dynamic Computed Tomography for Myocardial Perfusion Assesment (ULYSSES Study).

    NCT03917199 · start 2016-11

    Registered record
    Registry ID
    NCT03917199
    Conditions
    Myocardial Perfusion Imaging; Computed Tomography; Coronary Artery Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-11
    Completion
    2019-07-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Perfusion Imaging; Computed Tomography; Coronary Artery Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Simultaneous Assessment of FFR and SPECT

    NCT02749045 · start 2016-07

    Registered record
    Registry ID
    NCT02749045
    Conditions
    Coronary Artery Disease
    Interventions
    SPECT imaging
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2016-07
    Completion
    2021-06
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionSPECT imaging
    PhaseNot applicable
    Registry statusTerminated

  • Perfusion Imaging With Myocardial Contrast Echocardiography in HCM

    NCT02560467 · start 2015-12-01

    Registered record
    Registry ID
    NCT02560467
    Conditions
    Hypertrophic Cardiomyopathy
    Interventions
    Echo and myocardial contrast echocardiography perfusion imaging
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-12-01
    Completion
    2019-09-15
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertrophic Cardiomyopathy
    InterventionEcho and myocardial contrast echocardiography perfusion imaging
    PhaseNot applicable
    Registry statusUnknown

  • Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

    NCT02130453 · start 2014-09-30

    Registered record
    Registry ID
    NCT02130453
    Conditions
    Ischemia
    Interventions
    Regadenoson
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-09-30
    Completion
    2024-06-28
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemia
    InterventionRegadenoson
    PhasePhase 4
    Registry statusCompleted

  • Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension

    NCT02220634 · start 2014-08

    Registered record
    Registry ID
    NCT02220634
    Conditions
    Pulmonary Hypertension
    Interventions
    Regadenoson
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2014-08
    Completion
    2017-05-25
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Hypertension
    InterventionRegadenoson
    PhaseNot applicable
    Registry statusTerminated

  • Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

    NCT01949844 · start 2014-05-16

    Registered record
    Registry ID
    NCT01949844
    Conditions
    Coronary Artery Disease; CAD
    Interventions
    regadenoson; Optimark®; Myocardial perfusion MRI
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-05-16
    Completion
    2017-10-23
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; CAD
    Interventionregadenoson; Optimark®; Myocardial perfusion MRI
    PhaseNot applicable
    Registry statusCompleted

  • Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

    NCT01710254 · start 2013-01

    Registered record
    Registry ID
    NCT01710254
    Conditions
    Atrial Fibrillation; Coronary Artery Disease
    Interventions
    Regadenoson MRI; Gadobenate dimeglumine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-01
    Completion
    2016-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Coronary Artery Disease
    InterventionRegadenoson MRI; Gadobenate dimeglumine
    PhasePhase 2
    Registry statusCompleted

  • Regadenoson and Adenosine

    NCT01809743 · start 2013-01

    Registered record
    Registry ID
    NCT01809743
    Conditions
    Coronary Artery Disease
    Interventions
    Regadenoson central -central; Regadenoson peripheral - peripheral; Regadenoson central - peripheral; Regadenoson peripheral - central; Adenosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-01
    Completion
    2013-10
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease
    InterventionRegadenoson central -central; Regadenoson peripheral - peripheral; Regadenoson central - peripheral; Regadenoson peripheral - central +1 more
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging

    NCT02608944 · start 2012-09-30

    Registered record
    Registry ID
    NCT02608944
    Conditions
    MRI Scans
    Interventions
    Adenosine; Regadenoson; O-15 labeled radioactive water; MRI; PET Imaging
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2012-09-30
    Completion
    2019-06-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMRI Scans
    InterventionAdenosine; Regadenoson; O-15 labeled radioactive water; MRI +1 more
    PhaseNot applicable
    Registry statusWithdrawn

  • Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI

    NCT01655043 · start 2012-09

    Registered record
    Registry ID
    NCT01655043
    Conditions
    Myocardial Ischemia
    Interventions
    Regadenoson; gadofoveset trisodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-09
    Completion
    2014-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Ischemia
    InterventionRegadenoson; gadofoveset trisodium
    PhasePhase 2
    Registry statusCompleted

  • Microvascular Blood Flow in Sickle Cell Anemia

    NCT01566890 · start 2012-07

    Registered record
    Registry ID
    NCT01566890
    Conditions
    Sickle Cell Disease; Sickle Cell Anemia
    Interventions
    regadenoson infusion with contrast-enhanced ultrasound; contrast-enhanced ultrasound; contrast-enhanced ultrasound; contrast-enhanced ultrasound; contrast-enhanced ultrasound
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-07
    Completion
    2020-11-16
    Enrolment
    91

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease; Sickle Cell Anemia
    Interventionregadenoson infusion with contrast-enhanced ultrasound; contrast-enhanced ultrasound; contrast-enhanced ultrasound; contrast-enhanced ultrasound +1 more
    PhaseNot applicable
    Registry statusCompleted